RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program New York, NY - May 29, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is
RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program
New York, NY - May 21, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Dr. Johanna Bendell, Director of the Drug Development Unit at Sarah Cannon Research Center
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting
New York, NY - April 27, 2020 - Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “RGX-104,
Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of